Anna Sundlöv nominated to the board of directors in Spago Nanomedical
Anna Sundlöv, clinical oncologist specialized in radionuclide therapy of cancer, is nominated to the board of Spago Nanomedical.
“Anna brings expertise that is highly relevant to the Tumorad project for development of a new radionuclide therapy for cancer. The project has gained from the progress in the SpagoPix project that is now being prepared for clinical development. The progress allows us to increase the pace of development towards the clinic also for Tumorad”, says Eva Redhe, Chair of Spago Nanomedical.
Anna Sundlöv is senior consultant in medical oncology, specialized in endocrine tumors and radionuclide therapy. She is also Head of the Oncology Clinical Research Unit at Skåne University Hospital and has previously held leading positions in the pharmaceutical industry.
The other members of the board, Eva Redhe (chair), Andreas Bunge, Peter Wulff, Peter Leander, and Sten Nilsson, are nominated for re-election. The Annual General Meeting will be held in Lund on May 17, 2017.
The nomination is supported by shareholders controlling 40.1% of the company shares, including Peter Lindell, Eva Redhe, Mikael Lönn, and Andreas Bunge.
For further information, contact Mats Hansen, CEO Spago Nanomedical AB, +46 767 764294, email@example.com.
Spago Nanomedical (AktieTorget Stockholm: SPAG) develops nanomaterials for cancer diagnostics and therapy. The company´s development activities are primarily focused on the cancer selective MRI-contrast agent SpagoPix, and the Tumorad®-project for cancer selective radionuclide therapy of cancer. The business concept of Spago Nanomedical is to develop projects from explorative to regulatory preclinical or early clinical phase, and then out-license or enter partnership for continued development of the projects to market launch. Spago Nanomedical collaborates with well-established and reputable patent consultants to continuously strengthen the intellectual property protection of the projects.
The aim of SpagoPix is to improve cancer diagnostics using magnetic resonance imaging (MRI) by facilitating early discovery of tumors and metastases. Early discovery improves the chances of efficient treatment and survival of cancer patients. Tumorad® is a further development of the company´s proprietary nanoparticles with the purpose of delivering radionuclides for tumor selective radiation therapy of cancer. Access to new therapies is essential for effective treatment of many forms of cancer.
For further information, see www.spagonanomedical.se.